In this article (), which was published in the November 1, 2017, issue of Clinical Cancer Research (1), the two lines in Fig. 3B denoting IC50 for noncarriers versus those with BRCA1/2 mutations were reversed. The corrected version of Fig. 3 is provided below. The publisher regrets this error.
References
1.
Dhawan
MS
, Bartelink
IH
, Aggarwal
RR
, Leng
J
, Zhang
JZ
, Pawlowska
N
, et al Differential toxicity in patients with and without DNA repair mutations: Phase I Study of Carboplatin and Talazoparib in advanced solid tumors
. Clin Cancer Res
2017
;23
:6400
–10
.
RSS Feeds